PD-1 membrane-coated RSL3 nanoparticles (PD-1@RSL3 NPs) were shown in preclinical models to enhance breast cancer treatment by inducing tumor ferroptosis, disrupting the PD-1/PD-L1 axis, and activating antitumor immunity, leading to delayed tumor progression and improved survival [150,151]. The gene discussed is CD274; the disease is neoplasm.